Spero Therapeutics (SPRO) Payables (2016 - 2026)
Spero Therapeutics posted quarterly Payables of $217000.0 for Q1 2026, down 87.71% year-on-year from $1.8 million in Q1 2025, and down 68.69% on a QoQ basis from $693000.0 in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of Payables data on file, last reported at $217000.0 in Q1 2026.
- For the quarter ending Q1 2026, Payables fell 87.71% year-over-year to $217000.0; the trailing twelve-month figure through Mar 2026 stood at $217000.0 (down 87.71% YoY), and the FY2025 full-year result was $693000.0, down 90.51% from the prior year.
- Payables for Q1 2026 stood at $217000.0, down from $693000.0 in the prior quarter.
- Across five years, Payables topped out at $7.3 million in Q4 2024 and bottomed at $217000.0 in Q1 2026.
- The 5-year median for Payables is $1.4 million (2025), against an average of $2.2 million.
- The widest annual swing landed in 2024, when Payables surged 452.13%; it then tumbled 90.51% in 2025.
- A 5-year view of Payables shows it stood at $617000.0 in 2022, then jumped by 123.34% to $1.4 million in 2023, then surged by 430.19% to $7.3 million in 2024, then plunged by 90.51% to $693000.0 in 2025, then plunged by 68.69% to $217000.0 in 2026.
- The last three Payables figures came in at $217000.0 (Q1 2026), $693000.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | 217,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 217,000.00 |
| Dec 31, 2025 | 693,000.00 |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 780,000.00 |
| Mar 31, 2025 | 1.77 Mn |
| Dec 31, 2024 | 7.31 Mn |
| Sep 30, 2024 | 6.09 Mn |
| Jun 30, 2024 | 2.70 Mn |
| Mar 31, 2024 | 3.07 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 1.31 Mn |
| Mar 31, 2023 | 583,000.00 |
| Dec 31, 2022 | 617,000.00 |
| Sep 30, 2022 | 2.58 Mn |
| Jun 30, 2022 | 1.71 Mn |
| Mar 31, 2022 | 4.78 Mn |
| Dec 31, 2021 | 1.10 Mn |
| Sep 30, 2021 | 3.16 Mn |
| Jun 30, 2021 | 1.63 Mn |
| Mar 31, 2021 | 3.83 Mn |
| Dec 31, 2020 | 1.16 Mn |
| Sep 30, 2020 | 2.48 Mn |
| Jun 30, 2020 | 1.56 Mn |
| Mar 31, 2020 | 8.95 Mn |
| Dec 31, 2019 | 4.15 Mn |
| Sep 30, 2019 | 2.52 Mn |
| Jun 30, 2019 | 1.04 Mn |
| Mar 31, 2019 | 557,000.00 |
| Dec 31, 2018 | 3.60 Mn |
| Sep 30, 2018 | 1.36 Mn |
| Jun 30, 2018 | 705,000.00 |
| Mar 31, 2018 | 982,000.00 |
| Dec 31, 2017 | 3.47 Mn |
| Sep 30, 2017 | 2.01 Mn |
| Dec 31, 2016 | 1.14 Mn |